Hemostats are normally used in surgical procedures only when conventional bleeding control methods are ineffective or impractical. The hemostat market offers opportunities as customers seek products that better meet their needs. Above and beyond having hemostats that are effective and reliable, additional improvements that they wish to see in hemostat products include: laparoscopy-friendly; work regardless of whether the patient is on anticoagulants or not; easy to prepare and store, with a long shelf life; antimicrobial; transparent so that the surgeon continues to have a clear field of view; and non-toxic, i.e. preferably not made from human or animal materials.
Hemostat sales are being driven by several factors. These include the growth in the volume of inpatient and of ambulatory same-day surgeries, as well as the growth in minimally-invasive surgical procedure volumes. Effective hemostats may also reduce the time spent in the operating suite, which directly saves both surgeons and hospitals time and money. If the products can also reduce the risk of adhesions, then the patient may be able to avoid a second surgery sometime down the road.
Selected Manufacturers of Hemostats
|Baxter||FloSeal Flowable Hemostat|
|Baxter||Hemopatch Sealing Hemostat|
|Baxter||Gelfoam Plus Hemostasis Kit|
|B Braun||SanguStop Collagen Hemostat|
|Covalon Technologies Ltd||CovaStatª|
|CryoLife||PerClot¨ Powdered Hemostatic Agent|
|Ethicon (JNJ)||Surgifoam¨ Family of Products,|
|Ethicon (JNJ)||Surgicel¨ Family of Absorbable Hemostats,|
|Ethicon (JNJ)||Surgiflo¨ Hemostatic Matrix|
(Note: Status on these products provided in Report #S290.)
Source: MedMarket Diligence, LLC; Report #S290.
Most markets for hemostats (as well as for sealants and glues) are experiencing very strong competition, and the US market, although the largest, is also saturated for many medical devices and products. Price controls are high priority in the European Union in order to control healthcare budgets. Japan, despite recent legislation making entry slightly easier, remains a tough market to crack. The easier-entry markets tend to be outside of the EU and Japan.
However, emerging markets are often characterized by fragile or unsteady economies, and healthcare markets that may not be ready to receive the more advanced sealant, glue and hemostat products. These hurdles must be overcome using shrewd market strategies and local offices in order to gain a foothold. Not all companies have the funds required to get into these markets directly, in which case a joint venture may be the best route.